Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

25,756 signal articles · 199 in last 24h · 123,545 total before filter · latest 20m ago
199last 24h
1245last 7d
206● bullish (7d)
145● bearish (7d)
205publishers
AllMacro215Earnings429M&A99Regulatory21Product12Analyst9
✕ clear all filtersticker: NVDASentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Forget P&G: This Defensive Cash-Flow Powerhouse Just Beat Earnings and Is a Best Buy Today
24/7 Wall St.68d agobullish
Forget P&G: This Defensive Cash-Flow Powerhouse Just Beat Earnings and Is a Best Buy Today

Procter & Gamble (NYSE:PG) is the household name every retirement portfolio reaches for when markets get choppy, and its $350.4 billion market cap makes it the default consumer defensive trade on every desk. The internals tell a different story. The Crowded Trade Is Quietly Cracking P&G beat its most recent quarter, but the internals are ... Forget P&G: This Defensive Cash-Flow Powerhouse Just Beat Earnings and Is a Best Buy Today

Up 23% From Its 52-Week Low: 1 Critical Metric That Explains Why I’m Standing Pat on Coca-Cola Stock
24/7 Wall St.69d agoneutral
Up 23% From Its 52-Week Low: 1 Critical Metric That Explains Why I’m Standing Pat on Coca-Cola Stock

At $80.91, Coca-Cola (NYSE:KO) sits in a holding pattern. Shares have rallied roughly 23% off the 52-week low and now trade where high risk-free Treasury yields are squeezing defensive staple multiples. Coca-Cola is the largest nonalcoholic beverage system in the world, anchored by sparkling soft drinks and increasingly carried by double-digit volume growth in Coca-Cola ... Up 23% From Its 52-Week Low: 1 Critical Metric That Explains Why I’m Standing Pat on Coca-Cola Stock

This $15 Billion Operational Beat Just Rewrote the Entire Bear Thesis for AbbVie
24/7 Wall St.69d agobullish
This $15 Billion Operational Beat Just Rewrote the Entire Bear Thesis for AbbVie

For income investors weighing biopharma exposure, the dividend question on AbbVie (NYSE:ABBV) just got a lot easier to answer. The company posted $15.002 billion in Q1 2026 revenue, beating consensus by $284 million, and management raised full-year adjusted EPS guidance to $14.08 to $14.28. With the stock yielding nearly 3%, the question is whether the ... This $15 Billion Operational Beat Just Rewrote the Entire Bear Thesis for AbbVie

What investors should know before hopping on SpaceX options trades
Yahoo Finance Video69d agoneutralVIDEO
What investors should know before hopping on SpaceX options trades

While SpaceX (SPCX) holds onto stock gains in Tuesday's session, the options market has been abuzz today as more traders chase options contracts on the space company. YieldMax ETFs chief strategist Mike Khouw comes on Market Domination to speak more about what retail investors should beware of when hopping into options trades on a company fresh off of its IPO.

XRP Holders With 1 Million Coins Now Own 74% of the Supply
24/7 Wall St.69d agoneutral
XRP Holders With 1 Million Coins Now Own 74% of the Supply

For the past six months, XRP (CRYPTO:XRP) slid lower as the Iran war battered the whole market, and plenty of holders gave up and sold. However, the biggest holders did the exact opposite. Wallets holding a million coins or more now own almost three-quarters of all the XRP in existence, and they did that by ... XRP Holders With 1 Million Coins Now Own 74% of the Supply

Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?
24/7 Wall St.69d agobullish
Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Moderna (NASDAQ:MRNA) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the mRNA pioneer. The move pushes Moderna stock to +94% year to date (YTD), easily the best performance in the major vaccine cohort. By comparison, Pfizer (NYSE:PFE) stock is ... Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?